STAT
DECEMBER 20, 2022
Lots of people struggle to get enough sleep — and the responsibility for fixing the problem tends to fall on the individual. Experts offer advice like reducing screen time, exercising more, or just going to bed earlier in the evening. But many restless nights can’t be solved with blackout curtains, ear plugs, or other typical suggestions.
PharmaVoice
DECEMBER 22, 2022
Art and science are often viewed as diametric opposites, but these industry insiders say their passion for painting blends into their pharma work.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 19, 2022
A collaboration between academic centres in the UK has won government funding for a digital approach to dysfunctional breathing or dyspnoea, a symptom that affects around 10% of the population. The Engineering and Physical Sciences Research Council (EPSRC) has set aside £400,000 (almost $490,000) for the project, which will help fund work at the Universities of Plymouth, Salford and Stirling, and the Glasgow School of Art.
Pharmaceutical Technology
DECEMBER 21, 2022
Moderna and the UK government have entered a ten-year strategic collaboration to build a messenger ribonucleic acid (mRNA) research, development and manufacturing facility in the country. The latest development comes after the parties announced an agreement in principle in June this year. This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
DECEMBER 22, 2022
Sepsis, a deadly overreaction of the immune system to infection, has befuddled clinicians and researchers for decades. Covid-19 made things worse. The early signs and symptoms of sepsis mimic those of both Covid-19 and influenza: fever, chills, dry cough, shortness of breath, fatigue, muscle or body aches, sore throat, nasal congestion, runny nose, and more.
PharmaVoice
DECEMBER 22, 2022
New Alzheimer's drugs are poised to change the market — and in preclinical arenas, researchers are learning more and more about the disease.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 23, 2022
Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The companies entered the initial agreement in September last year. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.
STAT
DECEMBER 20, 2022
Americans have been warned — again — about lax attention to routine vaccinations. This time the warning comes from measles , an age-old, vaccine-preventable disease, with an outbreak in central Ohio among nearly 80 children and counting, almost all of them unvaccinated against measles. Once well-controlled in the U.S., which has maintained “measles elimination status” for almost 20 years, this disease may no longer be a rarity as millions of children in the U.S. are m
PharmaVoice
DECEMBER 19, 2022
A series of small successes showed promise for the future of blood cancer treatments, particularly in the arena of drug combinations.
pharmaphorum
DECEMBER 22, 2022
Construction will start early next year of a new manufacturing centre in the UK with the capacity to produce 250 million vaccine doses per year, the centrepiece of a 10-year alliance between the government and US biotech Moderna. The government said today it has finalised the partnership – agreed in principle earlier this year and estimated to be worth in the region of $1.2 billion – although it is not revealing the financial details, as these are “commercially sensitive.” The overar
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Technology
DECEMBER 18, 2022
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting variation to the marketing authorization (MA) for Moderna ’s Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214) booster for usage in children aged six to 11 years. The 0.25mL dose of the booster vaccine could potentially be used in the European Union (EU) following authorisation in these children a minimum of three months following a previous Covid-19 vaccination.
STAT
DECEMBER 23, 2022
Flu activity across the United States continues to decline, though it remains at high levels in most parts of the country, the Centers for Disease Control and Prevention reported Friday in its weekly influenza update for the week ending Dec. 17. The percentage of people seeking medical care for influenza-like illness dropped for the third straight week, and hospitalizations due to flu declined for the second week in a row.
PharmaVoice
DECEMBER 19, 2022
Was it a public health victory? Or did mpox ‘burn itself out?’ An epidemiologist weighs in.
pharmaphorum
DECEMBER 19, 2022
The US Food and Drug Administration (FDA) has approved Swiss drugmaker Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firedenovec-vncg) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumours. Bladder cancer is one of the more common forms of cancer.
European Pharmaceutical Review
DECEMBER 21, 2022
Fluoxetine was approved to treat depression 35 years ago. Since then, there have been few breakthrough innovations in treating neuropsychiatric diseases such as anxiety, depression, substance use disorders (SUDs), and post-traumatic stress disorder (PTSD). For many indications, progress has been incremental. Psychedelic research, in particular, is gaining momentum. .
STAT
DECEMBER 21, 2022
Even as the United States has made commitments to health as a human right and reversing health disparities and has invested significantly in orphan diseases, it continues to overlook sickle cell disease (SCD), the most common inherited blood disorder worldwide, which affects more than 100,000 Americans , most of whom are Black or Hispanic American. As hematologists who take care of people with sickle cell disease , it’s disheartening to see this condition receive only a fraction of the at
PharmaVoice
DECEMBER 21, 2022
For Lightship, increasing patient access to clinical trials is about meeting them where they are — literally.
Pharmaceutical Technology
DECEMBER 22, 2022
Fentanyl is a powerful opioid (a narcotic analgesic that is at least partly synthetic) that is being trafficked in increasing quantities from Mexico to the US by cartels. The Drug Enforcement Administration (DEA) recently announced that it had seized 10,000 pounds of illicit fentanyl in 2022 and pointed out that this volume represented enough fentanyl to kill every American.
European Pharmaceutical Review
DECEMBER 22, 2022
The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. mRNA technologies have emerged as an innovative and effective approach to developing new drugs that can potentially transform existing therapies or target difficult‑to‑treat indications including respiratory, cardiac, metabolic and autoimmune diseases, as well as cancer.
STAT
DECEMBER 21, 2022
This is part of a series of snapshots from post-Roe America. H e loved peaches. He loved ice cream. He loved blueberry waffles, evenly gridded, which she’d pulled from the crinkly package in the freezer and popped in the toaster to eat on her way to work. L. knew all this from the way he moved, the way he made her sick. His name was Kai. He was due on December 18.
PharmaVoice
DECEMBER 20, 2022
A look back at some of the most inspirational quotes from the Women of the Week podcasts in 2022.
Pharmaceutical Technology
DECEMBER 19, 2022
Sanofi has extended the partnership with Innate Pharma for natural killer (NK) cell therapeutics in oncology. With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. Under the latest licence deal, Sanofi will make an upfront payment of $26.4m (€25m) to Innate.
European Pharmaceutical Review
DECEMBER 19, 2022
A new £2.4 million Phase III trial will determine if ketamine-assisted therapy can help those with severe alcohol use disorder to stay off alcohol for longer. Led by the University of Exeter and funded by the Medical Research Council (MRC) and the National Institute for Health and Care Research (NIHR), “[t]his is the largest trial of its kind in the world and builds on our earlier, smaller positive trial,” stated Professor Anne Lingford-Hughes, Professor of Addiction Biology at Imperial College
STAT
DECEMBER 22, 2022
Life expectancy for Americans fell for the second straight year in 2021, largely driven by increases in deaths from Covid-19 and drug overdoses, according to new data from the Centers for Disease Control and Prevention. A baby born in the U.S. in 2021 has a life expectancy of 76.4 years, down from 77 years in 2020 and the lowest level the CDC has recorded since 1996.
pharmaphorum
DECEMBER 20, 2022
In the past two decades, global spending on health has doubled. Yet, optimal healthcare remains out of reach for most of the world as many countries continue to struggle with the burden of disease, growing complexity of healthcare, and persistence of health disparities. The problem is not a lack of innovation. Advancements in technology and medicine have made it possible to improve nearly every aspect of care by analysing vast amounts of data, uncovering insights into each person’s disease and e
Digital Pharmacist
DECEMBER 22, 2022
The role of the community pharmacy has increased tremendously especially during the COVID pandemic. For pharmacies, it is important to understand the needs of the patients, and the services that patients are looking for so patient expectations can not only be met but exceeded. . In this blog, we will discuss pharmacy trends to look out for in 2023 so your business can be as prepared as possible in the New Year.
European Pharmaceutical Review
DECEMBER 21, 2022
Ten young children all under the age of 5, who born with immunodeficiency disorder Artemis-SCID, have been able to return to normal life, thanks to a new gene therapy which allows diagnosed babies to be treated with their own cells, a significant milestone since the condition is normally treated via bone marrow transplant from a donor. A breakthrough treatment for Artemis-SCID.
STAT
DECEMBER 23, 2022
SAN FRANCISCO — A prominent California medical school has apologized for conducting dozens of unethical medical experiments on at least 2,600 incarcerated men in the 1960s and 1970s, including putting pesticides and herbicides on the men’s skin and injecting it into their veins. Two dermatologists at the University of California, San Francisco — one of whom remains at the university — conducted the experiments on men at the California Medical Facility, a prison hospit
PharmExec
DECEMBER 22, 2022
Michael Ku, VP of global clinical supply at Pfizer, shares insights for the c-suite as well as reveals behind-the-scenes insight into Pfizer’s ability to deliver a COVID-19 vaccine swiftly.
The Guardian - Pharmaceutical Industry
DECEMBER 17, 2022
Doctors say CDC’s softer guidelines ‘tossing aside’ safety limits put lives at risk as opioid epidemic continues to rage in the country The Centers for Disease Control and Prevention (CDC) has been accused of bowing to drug industry pressure after releasing new guidelines that doctors say put lives at risk by rowing back on warnings about the dangers of opioid prescribing.
European Pharmaceutical Review
DECEMBER 21, 2022
The US Food and Drug Administration (FDA) created live biotherapeutic products (LBP) as a new category in the 2012 guidelines. 1 It defined LBPs as drug products containing live microorganism(s) to be used to prevent, treat or cure a disease or condition in human beings. 1 The European Directorate for the Quality of Medicines & Healthcare (EDQM) also accepted LBP as a new category of medicinal products for the European market in 2019. 2.
STAT
DECEMBER 23, 2022
Congress is expected to pass a massive $1.7 trillion omnibus spending package that includes numerous provisions aimed at addressing the opioid epidemic. I have been advocating for greater access to opioid addiction treatment for more than two decades. While the spending package contains many positive opioid treatment reforms, I am deeply concerned that Congress and others without on-the-ground experience will continue pushing dangerous policies to solve the opioid epidemic in the next Congress.
Drug Patent Watch
DECEMBER 19, 2022
Annual Drug Patent Expirations for OFORTA Oforta is a drug marketed by Sanofi Aventis Us and is included in one NDA. There is one patent protecting this drug. This drug…. The post New patent expiration for Sanofi Aventis drug OFORTA appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
DECEMBER 19, 2022
Amicus Therapeutics could be just weeks away from getting EU approval for its new Pompe disease therapy Pombiliti after getting a positive opinion on the drug from the EMA’s human medicines committee. The CHMP said late last week it was recommending Pombiliti (cipaglucosidase alfa or ATB200) as an infused therapy for late-onset Pompe disease in adults given in combination with the enzyme stabiliser miglustat in a regimen known as AT-GAA.
EMCrit Project
DECEMBER 19, 2022
This is SIESTA syndrome. The patient is locked in a cycle of unconsciousness, punctuated with brief episodes of agitation. Most of the time the patient is sedated to the point of having minimal EEG activity, which may hinder their ability to regain consciousness. . EMCrit Project by Josh Farkas.
Expert insights. Personalized for you.
363 
Let's personalize your content